679 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This research provides compelling evidence that GLP-1 receptor agonists could represent a novel and effective strategy for smoking cessation. The observed reductions in nicotine seeking and withdrawal symptoms, couple…
This network meta-analysis provides crucial evidence that could significantly impact clinical guidelines for managing Type 2 Diabetes patients with high cardiovascular risk. The identification of specific GLP-1 recept…
This research provides robust real-world evidence confirming the effectiveness of GLP-1 therapies in a diverse Middle Eastern population, mirroring results from controlled clinical trials. The observed significant red…
This research provides a more robust and accurate framework for predicting the efficacy and optimizing the dosing of GLP-1 receptor agonists like liraglutide. By precisely accounting for target-mediated drug dispositi…
This case series provides crucial preliminary evidence suggesting that GLP-1 RAs can be a safe and effective therapeutic option for weight management in older adults, challenging previous hesitations regarding their u…
This study provides critical safety reassurance regarding the use of these widely prescribed antidiabetic medications, particularly for hematologic malignancy risk. The agent-specific findings highlight the importance…
This case, if substantiated by detailed clinical data, suggests that Semaglutide could represent a novel and effective therapeutic option for patients with Ulcerative Colitis, particularly those who also suffer from o…
This review significantly advances our understanding of GLP-1's extensive therapeutic potential, moving beyond its established role in metabolic health. The detailed exploration of its neuroprotective mechanisms sugge…
This research provides critical reassurance regarding the safety and efficacy of GLP-1 receptor agonists for obesity management. The preservation of muscle mass and function during weight loss is a significant clinica…
This pooled analysis strongly suggests that Tirzepatide is a highly effective add-on therapy for patients with Type 2 Diabetes who are not achieving optimal glycemic control with basal insulin alone. The dual action a…
These findings are highly significant, as they demonstrate that Tirzepatide, a dual GLP-1/GIP receptor agonist, offers substantial benefits beyond glycemic control and weight loss, directly addressing critical cardiov…
This case report highlights a potential novel therapeutic avenue for ulcerative colitis, suggesting that GLP-1 RAs like semaglutide might offer benefits beyond metabolic control. The observed symptomatic remission and…
This study provides compelling real-world evidence that combining GLP-1 therapy with digital coaching is a highly effective and scalable strategy for obesity management, particularly in diverse populations. The high r…
This pilot study provides compelling evidence that a simple, scalable text messaging program can significantly improve the transition process from basal insulin to GLP-1 RAs, particularly within safety-net populations…
This case report highlights a novel and important consideration for healthcare providers prescribing semaglutide to patients with lower limb amputations. The rapid and significant weight loss induced by GLP-1 agonists…
The successful completion of this trial could lead to the availability of a new semaglutide injection, potentially increasing access and offering more treatment options for Type 2 Diabetes patients. If the investigati…
This large-scale, pragmatic trial is crucial because it directly compares two leading therapeutic strategies for Type 2 Diabetes patients at high risk for cardiovascular and kidney complications. The findings could pr…
This pilot study holds significant promise, as successful integration of weight management strategies could potentially improve treatment efficacy and long-term outcomes for endometrial cancer patients. If tirzepatide…
Finding effective strategies to prevent weight regain after discontinuing GLP-1 agonists is critically important for long-term obesity management and patient well-being. This trial could provide evidence for new stand…
This comprehensive synthesis underscores the critical role of inflammation as a shared, actionable therapeutic target for both cardiovascular disease and diabetes mellitus, moving beyond traditional single-disease app…
This study provides novel mechanistic insights into how Semaglutide exerts its therapeutic effects beyond simply delaying gastric emptying. Understanding these specific changes in gastric electrical activity could opt…
This study provides crucial evidence that a new, potentially more accessible semaglutide formulation can offer comparable efficacy and safety to the established reference drug for weight management. This could signifi…
This study provides crucial real-world evidence that polyethylene glycol loxenatide is a highly effective and safe treatment option for Type 2 diabetes, offering comparable benefits to the widely used semaglutide. The…
This research highlights a novel therapeutic potential for Semaglutide beyond its established roles in diabetes and obesity, suggesting it could directly address cardiovascular complications associated with sarcopenia…
The analysis revealed a consistent and significant deficiency in the use of objective functional measures across studies investigating semaglutide in frail HFpEF populations. Many existing reports relied heavily on su…
This research provides crucial insights into the genetic underpinnings of GLP-1 RA response, paving the way for personalized treatment strategies. By identifying individuals most likely to benefit or experience advers…
This real-world study provides crucial evidence supporting the clinical benefit and safety of escalating once-weekly semaglutide from 0.5 mg to 1.0 mg in patients with Type 2 Diabetes. The significant improvements in …
If successful, this study could establish semaglutide as a safe and effective treatment option for glucose control in patients with Type 2 Diabetes and End Stage Renal Disease on dialysis. This is a particularly chall…
The findings from this trial are profoundly significant, as oral semaglutide offers a highly effective, non-injectable treatment option for Type 2 Diabetes Mellitus. This oral formulation has the potential to revoluti…
Understanding the safety and tolerability of BI 1820237 is a critical first step in its development as a potential new treatment for overweight and obesity. If BI 1820237 demonstrates a favorable safety profile and pr…
This study addresses a critical need for practical, accessible dietary recommendations to complement GLP-1 RA therapy, potentially enhancing patient outcomes beyond just weight loss. If successful, it could provide a …
This study provides initial evidence that combining LY3457263 with tirzepatide could represent a more potent and effective strategy for treating obesity than existing monotherapies. The favorable safety profile and en…
This clinical trial is profoundly significant as it explores a novel and promising therapeutic approach for ADPKD, a disease with limited treatment options and a high burden on patients. If successful, this research c…
If tirzepatide proves safe and effective, it could represent a significant therapeutic advancement for individuals with Type 1 Diabetes who struggle with obesity or overweight. Currently, there are limited pharmacolog…
This systematic review highlights the significant therapeutic potential of incretin-based therapies for individuals struggling with binge eating disorder, offering a promising new avenue for treatment. Given that curr…
This study provides robust real-world evidence supporting the favorable cardiovascular safety profile of tirzepatide, particularly concerning heart failure and arrhythmias, in a diverse patient population. The consist…
This study provides crucial evidence that early intervention with tirzepatide and semaglutide can significantly mitigate the progression of atherosclerosis, a leading cause of morbidity and mortality worldwide. The ob…
This research provides crucial insights, strongly suggesting that the weight loss achieved with Semaglutide is the primary driver behind its beneficial effects on liver health in patients with Type 2 Diabetes Mellitus…
This real-world evidence strongly reinforces the efficacy and safety of Tirzepatide for managing Type 2 Diabetes and associated metabolic abnormalities in a broader, more diverse patient population than typically seen…